MDGL - Madrigal Pharmaceuticals

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Madrigal Pharmaceuticals names Mardi Dier as CFO
• Madrigal Pharmaceuticals GAAP EPS of -$5.68 misses by $0.42
• Paulson & Co. bolsters stakes in Newmark, NovaGold, Madrigal Pharmaceuticals
• Eli Lilly hurts NASH drug developers after mid-stage win for obesity therapy
• Madrigal Pharmaceuticals, Cerus among healthcare movers
• Karuna’s KarXT tops Evaluate’s most anticipated drug list
• Barron’s cites cancer and weight loss plays for biotech M&A
• Madrigal Pharmaceuticals says Baker Bros Advisors buys 131.4K shares in co through indirect interest
• Paulson & Co. closes stake in Newmont, boosts Horizon Therapeutics stake
• Madrigal adds former Sanofi executive as commercial chief
• Madrigal Pharmaceuticals GAAP EPS of -$5.34 misses by $0.38
• Akero slumps leading to mixed reactions in NASH space
• Madrigal Pharmaceuticals prices of $500 million stock offering
• Madrigal Pharmaceuticals announces proposed public offering
• Madrigal Pharma chief commercial officer leaving; shares down 3%
• Madrigal nabs FDA priority review for NASH drug
• Madrigal Pharmaceuticals appoints CEO
• Paulson takes new stakes in Newmont, Iveric Bio and Madrigal in Q2
• Drugmakers still chasing potentially lucrative NASH market, despite setbacks
• Madrigal Pharmaceuticals GAAP EPS of -$4.69